Orientations
MCV 5-dose Option Overview
This slide deck provides a concise overview of the 5-dose measles-containing vaccine (MCV) vial option for routine immunization programs. It is intended for EPI managers, immunization partners, and country decision-makers considering whether a switch from 10-dose to 5-dose measles or MR vials could improve coverage and reduce missed opportunities for vaccination.
The resource summarizes the rationale for the 5-dose option, expected program implications, product and cost considerations, cold chain requirements, and key questions for country decision-making. It also includes frequently asked questions to help teams assess whether the 5-dose presentation is a good fit for their context and how to plan for implementation.
Auteurs
Langues
- Anglais
Année de publication
2026
Type
Orientations
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Rougeole
- Rubéole
Mots-clés
- Présentation et emballage des vaccins
MCV5 PHASE 1
Vous pouvez trouver plus d’informations sur "MCV5 PHASE 1" dans les rubriques suivantes :
| Titre | Auteur | Année | Type | Langue |
|---|---|---|---|---|
| Measles and Measles-Rubella (MR) Vaccine Five-Dose Vial Presentation - Fact Sheet 2022 - 2023 | UNICEF, World Health Organization (WHO) | 2022 | Guidance | Anglais |
| MCV 5-dose Research and Resources | Linksbridge | 2022 | Report | Anglais |
| MCV 5-dose National Impact Assessment Tool | Linksbridge | 2026 | Tool | Anglais, Français |
| Experiences with the MCV 5-dose Switch from Africa’s EPI | UNICEF | 2024 | Case study | Anglais |
| How To Use: Step-by-Step Instructions for the MCV 5-dose National Impact Assessment Tool | Linksbridge | 2025 | User guide | Anglais |
| MCV 5-dose Option Overview | Linksbridge | 2026 | Guidance | Anglais |
| MCV 5-dose 2-Pager | Linksbridge | 2026 | Guidance | Anglais |
